Owlstone Medical

Owlstone Medical company information, Employees & Contact Information

Explore related pages

Related company profiles:

Owlstone Medical is developing a breathalyzer for disease. With a goal of finding ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health, and other conditions. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine. Do not forget to subsribe to our monthly LinkedIn newsletter to receive insights and news from across the breath research field. Breath Biopsy® aims to develop a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA® Breath Sampler ensures the reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using state-of-the-art chemical analysis technologies. Our aim is to develop tools, potentially based on our proven microchip chemical sensor technology (FAIMS), to detect validated biomarkers of disease. The Breath Biopsy platform provides biomarker discovery and validation capabilities to support the development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved. OMED Health is the patient-centric brand of Owlstone Medical, and offers non-invasive breath tests and longitudinal monitoring solutions for those suffering with their digestive health. Our Breath Biopsy Products and Services are available to academic, clinical, and pharma research partners who want to develop breath-based diagnostics for their own applications. Our products and services are for research use only. Not for use in diagnostic procedures. We are not recruiting right now, but you can connect with us via the button on our website and if an opportunity arises we think is suitable for you, we will reach out.

Company Details

Employees
183
Founded
-
Address
183 Cambridge Science Park, Cambridge,england,united Kingdom
Phone
4401223428200
Industry
Research
HQ
Cambridge, England
Looking for a particular Owlstone Medical employee's phone or email?

Owlstone Medical Questions

News

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round - Business Wire

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round Business Wire

Owlstone Medical gets up to US$49.1M to develop multi-cancer breath tests - Mugglehead Magazine

Owlstone Medical gets up to US$49.1M to develop multi-cancer breath tests Mugglehead Magazine

Owlstone Medical announces investment of up to $2.3 Million USD from the Cystic Fibrosis Foundation to develop a breath test for Pseudomonas aeruginosa detection in Cystic Fibrosis patients - Cambridge Network

Owlstone Medical announces investment of up to $2.3 Million USD from the Cystic Fibrosis Foundation to develop a breath test for Pseudomonas aeruginosa detection in Cystic Fibrosis patients Cambridge Network

Owlstone Medical chief's heartbreak leads to new hope in US-driven cancer programme - Business Weekly

Owlstone Medical chief's heartbreak leads to new hope in US-driven cancer programme Business Weekly

Owlstone Medical awarded £39m to detect cancer early in US - BusinessCloud

Owlstone Medical awarded £39m to detect cancer early in US BusinessCloud

Owlstone Medical announces $27 million USD first close in Series E financing round - PharmaTimes

Owlstone Medical announces $27 million USD first close in Series E financing round PharmaTimes

Owlstone Medical secures £22 million Series E Investment led by Ventura Capital - UK Tech Investment News

Owlstone Medical secures £22 million Series E Investment led by Ventura Capital UK Tech Investment News

Every breath counts; Utilizing breath biopsy technology to detect disease early - News-Medical

Every breath counts; Utilizing breath biopsy technology to detect disease early News-Medical

Owlstone Medical Gains $6.5M to Develop Breath-Based Diagnostics for Infectious Diseases - Medical Product Outsourcing

Owlstone Medical Gains $6.5M to Develop Breath-Based Diagnostics for Infectious Diseases Medical Product Outsourcing

Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease - FinancialContent

Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease FinancialContent

Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Management Across Seven Immune-Mediated Diseases - R&D World

Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Management Across Seven Immune-Mediated Diseases R&D World

Aviva invests in technology that detects early signs of cancer - Aviva corporate website

Aviva invests in technology that detects early signs of cancer Aviva corporate website

Owlstone Medical Receives CE Mark Approval For Pediatric Disease Breathalyzer - Med Device Online

Owlstone Medical Receives CE Mark Approval For Pediatric Disease Breathalyzer Med Device Online

Owlstone Medical presents data for breath biopsy tests - Home | Digital Health

Owlstone Medical presents data for breath biopsy tests Home | Digital Health

Owlstone Medical Wins up to $49.1 Million Award from ARPA-H to Develop At-home Multi-Cancer-Early Detection Tests - Business Wire

Owlstone Medical Wins up to $49.1 Million Award from ARPA-H to Develop At-home Multi-Cancer-Early Detection Tests Business Wire

Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy - Cambridge Network

Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy Cambridge Network

Owlstone Medical launches Breath Biopsy VOC Atlas® to unlock disease biomarkers in human breath - News-Medical

Owlstone Medical launches Breath Biopsy VOC Atlas® to unlock disease biomarkers in human breath News-Medical

Owlstone Medical Ltd : Quotes, Address, Contact - News-Medical

Owlstone Medical Ltd : Quotes, Address, Contact News-Medical

Owlstone Medical lands five-year deal with FDA - Business Weekly

Owlstone Medical lands five-year deal with FDA Business Weekly

World's first cancer breathalyser test trialled on 1,500 UK patients - The Mirror

World's first cancer breathalyser test trialled on 1,500 UK patients The Mirror

Top Owlstone Medical Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant